Pediatric drug allergy: a retrospective analysis of clinical features, laboratory parameters, and systemic inflammation indices
Main Article Content
Keywords
Pediatric drug allergy, Drug hypersensitivity reactions, Inflammatory biomarkers
Abstract
Background: This study aimed to investigate the potential utility of hematological parameters and systemic inflammatory indices as predictive biomarkers in pediatric patients with drug hypersensitivity reactions (DHRs).
Methods: We performed a retrospective review of medical records of children presenting to the Pediatric Allergy and Immunology Clinic at Fırat University Hospital, Turkey, between January 2019 and July 2025 with suspected DHRs. Demographic characteristics, clinical manifestations, reaction phenotypes, complete blood counts, and total immunoglobulin E (IgE) levels were analyzed. Inflammatory indices, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), eosinophil-to-lymphocyte ratio (ELR), and systemic immune–inflammation index (SII), were calculated subsequently.
Results: Among the 45 children included, drug allergy was confirmed in 14 (31.1%) children. Total IgE levels did not differ significantly between groups (P = 0.712). Monocyte counts were significantly higher in the patient group (P = 0.039), whereas eosinophil counts were elevated in the control group (P = 0.026). Lymphocyte (P = 0.002) and basophil counts (P = 0.002) were significantly lower in the patient cohort. No significant differences were observed in neutrophil or platelet counts. Regarding inflammatory indices, NLR (P = 0.007), PLR (P = 0.006), and SII (P = 0.007) were significantly increased in the patient group, whereas ELR did not differ significantly (P = 0.073).
Conclusion: In this small, single-center cohort (n = 45; confirmed DHR, n = 14), higher NLR, PLR, and SII were observed among children with confirmed DHRs. These preliminary findings suggest that readily available hematological indices may aid hypothesis generation and tentative risk stratification; however, they should be interpreted cautiously and require confirmation in larger prospective studies.
References
2. Gomes E, Brockow K, Kuyucu S, Saretta F, Mori F, Blanca-Lopez N, et al. Drug hypersensitivity in children: Report from the pediatric task force of the EAACI Drug Allergy Interest Group. Allergy. 2016;71(2):149–61. https://doi.org/10.1111/ all.12774
3. Piccorossi A, Liccioli G, Barni S, Sarti L, Giovannini M, Verrotti A, et al. Epidemiology and drug allergy results in children investigated in allergy unit of a tertiary-care pediatric hospital setting. Allergol Immunopathol (Madr). 2020;46(1):5. https://doi.org/10.1186/s13052-019-0753-4
4. Milosevic K, Malinic M, Plavec D, Lekovic Z, Lekovic A, Cobeljic M, et al. Diagnosing single and multiple drug hypersensitivity in children: A tertiary care center retrospective study. Children (Basel). 2022;9(12):1954. https://doi. org/10.3390/children9121954
5. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139(8):683–693. https://doi.org/10.7326/ 0003-4819-139-8-200310210-00012
6. Roberto B, Fabio C, Francesca M, Francesca S, Lucia L, Fabrizio F, et al. Management of the child with allergy to non-antibiotic drugs. Allergy. 2019;90(Suppl 3):5. https://doi. org/10.23750/abm.v90i3-S.8149
7. Thomson P, Hammond S, Naisbitt DJ. Pathology of drug hypersensitivity reactions and mechanisms of immune tolerance. Curr Allergy Clin Immunol. 2022;52(12):1379–90. https://doi.org/10.1111/cea.14235
8. Khan DA, Banerji A, Blumenthal KG, Phillips EJ, Solensky R, White AA, et al. Drug allergy: A 2022 practice parameter update. J Allergy Clin Immunol. 2022;150(6):1333–93. https:// doi.org/10.1016/j.jaci.2022.08.028
9. Zhang X, Hu F, Hana M, Wang X, Wang Q, Zhou K, et al. An updated review of the diagnostic methods in drug hypersensitivity reactions. Front Allergy. 2025;4:100045. https://doi. org/10.1016/j.allmed.2025.100045
10. Duque JSR, Cheuk DK, Chong PC, Ip P, Wong WH, Lee PP, et al. Risk factors for drug allergies in Chinese children. Allergy Asthma Proc. 2020;38(4):271–8. https://doi. org/10.12932/AP-191018-0417
11. Brandão LS, Nunes FA, Bastos PGA, Guerzet P, Lacerda AE, Piza CF, et al. Drug hypersensitivity reactions: Are there differences between children and adults? Allergy. 2019;143(2):AB160. https://doi.org/10.1016/j.jaci.2018.12.486
12. Yaytokgil ŞB, Vezir E. Characteristics of drug hypersensitivity reactions in children: A retrospective analysis in an allergy outpatient clinic. Turk J Child Health Dis. 2024;18(4):247–52. https://doi.org/10.12956/tchd.1462063
13. Bergmann M, Caubet JC. Specific aspects of drug hypersensitivity in children. Curr Pharm Des. 2016;22(45):6832–51. https://doi.org/10.2174/1381612822666160926105533
14. Yaytokgil ŞB, Demir KI, Topal ÖY, Metbulut AP, Çelik İK, Toyran M, et al. Evaluation of accompanying allergic disease in children with proven drug allergies. Turk J Med Sci. 2024;54(1):316–23. https://doi.org/10.55730/1300-0144.5793
15. Lezmi G, Alrowaishdi F, Bados-Albiero A, Scheinmann P, de Blic J, Ponvert CJ, et al. Non-immediate-reading skin tests and prolonged challenges in non-immediate hypersensitivity to beta-lactams in children. Pediatr Allergy Immunol. 2018;29(1):84–9. https://doi.org/10.1111/pai.12826
16. Shiohara T, Kano Y. A complex interaction between drug allergy and viral infection. Curr Opin Rheumatol Immunol. 2007;33(1):124–33. https://doi.org/10.1007/s12016-007-8010-9